
## Nicole Cotroneo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4917456/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>In Vitro</i> Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus. Microbiology Spectrum, 2022, 10, e0132121.	1.2	11
2	Evaluation of Tebipenem Hydrolysis by β-Lactamases Prevalent in Complicated Urinary Tract Infections. Antimicrobial Agents and Chemotherapy, 2022, 66, e0239621.	1.4	4
3	Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens. Microbial Drug Resistance, 2020, 26, 319-328.	0.9	11
4	In Vitro Activity Analysis of a New Polymyxin, SPR741, Tested in Combination with Antimicrobial Agents against a Challenge Set of Enterobacteriaceae , Including Molecularly Characterized Strains. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	5
5	Resistance among urinary tract pathogens collected in Europe during 2018. Journal of Global Antimicrobial Resistance, 2020, 23, 439-444.	0.9	18
6	<i>In Vitro</i> and <i>In Vivo</i> Characterization of Tebipenem, an Oral Carbapenem. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	20
7	Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	34
8	Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	27
9	The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017. PLoS ONE, 2019, 14, e0220265.	1.1	94